Orthofix Medical, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Orthofix Medical, Inc.
Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.
The “merger of equals” will bring together complementary spine surgery and orthopedic products including spine implants, biologics, limb-reconstruction devices and surgical planning and navigation software.
Simplify’s total disc replacement complements NuVasive’s C360 line of cervical repair surgery devices, addressing a market that could eventually be worth $2.6bn.
Global sales of orthobiologics products are expected to reach $2.8bn by 2024, a CAGR of 3.2%, led by the rising aging population and musculoskeletal disease.
- Implantable Devices
- Other Names / Subsidiaries
- Orthofix International N.V.
- Options Medical, LLC
- SeaSpine Holdings Corporation
- Spinal Kinetics, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.